| Abciximab + UFH (n=346) | Bivalirudin + UFH (n=162) | UFH only (n=253) | |
| Age in yrs (range) | 64±14.1 (25–99) | 65±13.0 (31–94) | 67±13.2 (30–96) |
| Male (%) | 77.7 | 72.2 | 66.8 |
| Diabetes (%) | 12.4 | 6.2 | 11.5 |
| Pre-procedure cardiogenic shock (%) | 7.8 | 6.2 | 4.7 |
| Drug eluting stent (at least one) (%) | 56.1 | 56.8 | 53.8 |
| No of stents | 1.4±0.9 | 1.4±0.8 | 1.4±0.9 |
| Single vessel PCI (%) | 91.3 | 87 | 89.3 |
| Three vessel PCI (%) | 1.4 | 1.9 | 2 |
| Radial procedure (%) | 28 | 26.5 | 31.2 |